Suppr超能文献

微小RNA-214-3p通过靶向肝细胞癌中的MELK抑制细胞增殖和细胞周期进程,并与癌症预后相关。

MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis.

作者信息

Li Yue, Li You, Chen Yao, Xie Qian, Dong Ningning, Gao Yanjun, Deng Huan, Lu Chunhua, Wang Suihai

机构信息

Institute of Antibody Engineering, Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, No. 1838, Guangzhou Avenue North, Guangzhou, 510515 China.

Department of Biotechnology, College of Life Science and Technology, Guangxi University, No. 100, Daxue Road, Nanning, 530004 Guangxi Province China.

出版信息

Cancer Cell Int. 2017 Nov 7;17:102. doi: 10.1186/s12935-017-0471-1. eCollection 2017.

Abstract

BACKGROUND

MicroRNAs are considered as potential regulators in various biological pathways and contribute to the diagnosis and prognosis of cancers. MicroRNA-214-3p (miR-214-3p) was proved to be correlated with various cancers in recent studies. However, the biological functions of miR-214-3p in hepatocellular carcinoma (HCC) and its association with the prognosis of HCC after liver transplantation are still unevaluated. Here we intended to elucidate the functional implication of miR-214-3p in regulation of cell proliferation and apoptosis and its potential prediction of clinical prognosis of HCC patients.

METHODS

Expressions of miR-214-3p in 98 HCC patients and three HCC cell lines were detected by quantitative reverse transcription PCR (qRT-PCR) to explore the association of miR-214-3p expression and clinicopathological characteristics. The effects of miR-214-3p on cell proliferation and apoptosis were examined by proliferation and flow cytometry assay, respectively. The direct target gene of miR-214-3p was also detected by luciferase reporter assay.

RESULTS

The effects of miR-214-3p on cell proliferation and apoptosis were examined by proliferation and flow cytometry assay, respectively. The direct target gene of miR-214-3p was also detected by luciferase reporter assay. The results showed that miR-214-3p expression was downregulated in primary HCC samples compared with normal liver tissues, and was decreased in HCC recurrence species compared with non-recurrence controls (P = 0.001). Low miR-214-3p level was associated with poor overall survival (OS) (Log rank P = 0.003) and recurrence-free survival (RFS) (Log rank P = 0.007). Moreover, miR-214-3p precursor transfection resulted in decreased cell proliferation, cell cycle arrest at G1 phase, and enhanced cell apoptosis in HepG2 and HUH-7 cells. Further investigation showed that miR-214-3p could regulate its target gene maternal embryonic leucine zipper kinase (MELK) by directly binding to MELK-3'-UTR.

CONCLUSIONS

miR-214-3p suppresses HCC progression by directly down-regulating MELK expression, indicating a potential therapeutic target for the treatment and prognosis of HCC patients.

摘要

背景

微小RNA被认为是各种生物途径中的潜在调节因子,有助于癌症的诊断和预后评估。近期研究证实,微小RNA-214-3p(miR-214-3p)与多种癌症相关。然而,miR-214-3p在肝细胞癌(HCC)中的生物学功能及其与肝移植后HCC预后的关系仍未得到评估。在此,我们旨在阐明miR-214-3p在调节细胞增殖和凋亡中的功能意义及其对HCC患者临床预后的潜在预测作用。

方法

采用定量逆转录聚合酶链反应(qRT-PCR)检测98例HCC患者及3种HCC细胞系中miR-214-3p的表达,以探讨miR-214-3p表达与临床病理特征的关系。分别通过增殖实验和流式细胞术检测miR-214-3p对细胞增殖和凋亡的影响。同时,采用荧光素酶报告基因实验检测miR-214-3p的直接靶基因。

结果

分别通过增殖实验和流式细胞术检测miR-214-3p对细胞增殖和凋亡的影响。采用荧光素酶报告基因实验检测miR-214-3p的直接靶基因。结果显示,与正常肝组织相比,原发性HCC样本中miR-214-3p表达下调,与未复发对照组相比,HCC复发样本中miR-214-3p表达降低(P = 0.001)。低miR-214-3p水平与较差的总生存期(OS)(Log秩检验P = 0.003)和无复发生存期(RFS)(Log秩检验P = 0.007)相关。此外,miR-214-3p前体转染导致HepG2和HUH-7细胞的细胞增殖减少、细胞周期阻滞于G1期并增强细胞凋亡。进一步研究表明,miR-214-3p可通过直接结合MELK-3'-UTR来调节其靶基因母源胚胎亮氨酸拉链激酶(MELK)。

结论

miR-214-3p通过直接下调MELK表达抑制HCC进展,提示其可能成为HCC患者治疗和预后评估的潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c3a/5678695/0f149cb85150/12935_2017_471_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验